What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Potassium-Sparing Diuretics: Vet Pharmacology

Name: Potassium-Sparing Diuretics: Vet Pharmacology
Creator: Dr. Zubair Khalid

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-09-20

Potassium-sparing diuretics are a small group of drugs that increase sodium and water excretion by the kidney while conserving potassium, and in veterinary medicine they are used almost entirely as add-on therapy for congestive heart failure in dogs and cats. The class splits into two mechanistic families. Aldosterone receptor antagonists, chiefly spironolactone, block the mineralocorticoid receptor in the distal nephron so aldosterone can no longer drive sodium reabsorption and potassium loss. Epithelial sodium channel blockers, amiloride and triamterene, plug the sodium channel itself. Spironolactone is the mainstay in veterinary cardiology. It is typically added to furosemide plus an ACE inhibitor or pimobendan in canine myxomatous mitral valve disease and dilated cardiomyopathy, and it is used in cats with cardiomyopathy-related heart failure. The clinical payoff is modest diuresis plus neurohormonal blockade and an antifibrotic effect that no loop diuretic provides. The clinical risk is hyperkalemia, especially when an ACE inhibitor, an angiotensin receptor blocker, or a potassium supplement is on board. This article covers the pharmacology, the evidence, the monitoring schedule, and the practical mistakes that cause trouble.

This article is educational and is not a substitute for veterinary diagnosis or treatment.

At a Glance

Feature	Spironolactone	Eplerenone	Amiloride	Triamterene
Drug class	Aldosterone receptor antagonist	Aldosterone receptor antagonist	Epithelial sodium channel blocker	Epithelial sodium channel blocker
Veterinary status	Mainstay, widely used in dogs and cats	Used in canine heart failure models, limited clinical veterinary use	Rarely used in veterinary cardiology	Rarely used in veterinary cardiology
Typical role	Add-on to furosemide plus ACE inhibitor or pimobendan	Alternative mineralocorticoid receptor antagonist	Adjunct potassium-sparing diuretic	Adjunct potassium-sparing diuretic
Route	Oral	Oral	Oral	Oral
Onset of diuretic effect	Slow, days	Slow, days	Slow, days	Slow, days
Duration	Once or twice daily dosing	Once daily	Once or twice daily	Once or twice daily
Prescription status	Prescription only	Prescription only	Prescription only	Prescription only
Key monitoring	Serum potassium, creatinine, renal values	Serum potassium, creatinine, renal values	Serum potassium, creatinine, renal values	Serum potassium, creatinine, renal values
Main adverse effect	Hyperkalemia, renal dysfunction	Hyperkalemia	Hyperkalemia	Hyperkalemia

What Potassium-Sparing Diuretics Are and What They Treat

A diuretic increases urine production. Most diuretics, including furosemide, act upstream in the nephron and deliver a large sodium load to the distal tubule, where aldosterone-sensitive cells exchange sodium for potassium. The result is sodium and water loss with potassium loss. Potassium-sparing diuretics work at the last step of that chain. They either block aldosterone from binding its receptor or block the epithelial sodium channel that aldosterone controls. Sodium excretion rises modestly and potassium stays in the body.

In veterinary practice, the phrase "k sparing diuretics" almost always means spironolactone. It is not used as a first-line diuretic for pulmonary edema. Furosemide does that job faster and more powerfully. Spironolactone is used for three reasons. First, it adds a small amount of diuresis without worsening potassium depletion. Second, it suppresses the renin-angiotensin-aldosterone system (RAAS), the hormone cascade that becomes chronically activated in heart failure and drives sodium retention, vasoconstriction, and cardiac fibrosis. Third, it has antifibrotic and antiarrhythmic effects that are independent of its diuretic action [1].

Labeled and accepted veterinary uses include:

Adjunct treatment of congestive heart failure in dogs, particularly myxomatous mitral valve disease (MMVD) and dilated cardiomyopathy (DCM)
Adjunct treatment of congestive heart failure in cats with cardiomyopathy
Management of ascites and edema where potassium conservation matters
Adjunct therapy in some cases of refractory heart failure where loop diuretic doses are escalating

What potassium-sparing diuretics do not cover:

They do not treat the underlying valve disease or myocardial disease
They do not replace furosemide for acute pulmonary edema
They do not correct ascites from liver disease or protein-losing nephropathy on their own
They do not lower blood pressure reliably in dogs or cats
They do not treat hypokalemia caused by vomiting, diarrhea, or renal tubular disease

How Potassium-Sparing Diuretics Work

The Aldosterone Receptor Antagonists

Aldosterone is a steroid hormone produced by the adrenal cortex. In the kidney, it binds the mineralocorticoid receptor in the principal cells of the late distal tubule and collecting duct. That binding increases expression of the epithelial sodium channel and the sodium-potassium ATPase, so sodium is reabsorbed and potassium is secreted into the urine. Aldosterone also acts on the heart, blood vessels, and fibroblasts, where it promotes fibrosis, endothelial dysfunction, and adverse remodeling [1].

Spironolactone is a competitive antagonist at the mineralocorticoid receptor. It occupies the receptor and prevents aldosterone from activating it. The downstream effect is increased sodium and water excretion with potassium retention. Spironolactone is a prodrug. It is metabolized to active compounds including canrenone and 7-alpha-thiomethylspirolactone, which carry much of the receptor-blocking activity. That metabolism explains the slow onset of the diuretic effect and the need for several days of dosing before the full renal effect appears.

Eplerenone is a more selective mineralocorticoid receptor antagonist. It binds the receptor with higher selectivity and has fewer antiandrogenic effects than spironolactone. Eplerenone has shown benefit in canine models of heart failure, and it is a reasonable alternative when spironolactone causes unacceptable endocrine side effects [1]. Clinical veterinary experience with eplerenone is much thinner than with spironolactone.

The Epithelial Sodium Channel Blockers

Amiloride and triamterene act one step downstream of the receptor. They physically block the epithelial sodium channel in the luminal membrane of the principal cell. Sodium cannot enter the cell, so the electrical gradient that drives potassium secretion is lost, and potassium is retained. These drugs do not block aldosterone itself, so aldosterone levels and receptor signaling remain intact. Their diuretic effect is weak and their potassium-sparing effect is direct. In veterinary medicine they are used far less often than spironolactone, and most of what is known about their clinical behavior comes from human medicine and general pharmacology.

Why the Distal Nephron Matters

The distal nephron handles only a small fraction of filtered sodium, so blocking it produces limited natriuresis. That is why potassium-sparing diuretics are never used alone for edema. Their value is additive and hormonal. When furosemide drives a large sodium load into the distal nephron, aldosterone is stimulated and potassium wasting accelerates. Adding spironolactone at that point blocks the aldosterone signal and limits the potassium loss. This is the pharmacological logic behind the standard combination of furosemide, an ACE inhibitor or pimobendan, and spironolactone in canine heart failure.

flowchart TD
    [Heart failure diagnosis]
    [Start furosemide]
    [Add ACE inhibitor or pimobendan]
    [Assess potassium and creatinine]
    [Add spironolactone]
    [Recheck potassium and creatinine]
    [Potassium high]
    [Potassium normal]
    [Reduce or stop spironolactone]
    [Continue and monitor]
    [Recheck in one to two weeks]
    [Adjust other drugs if needed]
    [Heart failure diagnosis] --> [Start furosemide]
    [Start furosemide] --> [Add ACE inhibitor or pimobendan]
    [Add ACE inhibitor or pimobendan] --> [Assess potassium and creatinine]
    [Assess potassium and creatinine] --> [Add spironolactone]
    [Add spironolactone] --> [Recheck potassium and creatinine]
    [Recheck potassium and creatinine] --> [Potassium high]
    [Recheck potassium and creatinine] --> [Potassium normal]
    [Potassium high] --> [Reduce or stop spironolactone]
    [Potassium normal] --> [Continue and monitor]
    [Continue and monitor] --> [Recheck in one to two weeks]
    [Reduce or stop spironolactone] --> [Adjust other drugs if needed]

Spironolactone in Veterinary Cardiology

The Pharmacodynamic Evidence

A preclinical study in Beagle dogs used a hyperaldosteronism model to measure how well spironolactone blocks aldosterone at the renal tubule. Aldosterone alone decreased sodium excretion by about 35 percent and increased urinary potassium concentration by about 25 percent. Oral spironolactone at 2 mg/kg completely reversed the aldosterone effect on the urinary sodium-to-potassium ratio, producing 88 percent inhibition. At 0.8 mg/kg, only partial reversal occurred, with 27.5 percent inhibition [2]. That dose-response relationship is the pharmacological basis for using a full receptor-blocking dose rather than a token dose in dogs with congestive heart failure.

Clinical Trials in Dogs

The evidence in dogs is mixed but informative. The BESST trial enrolled 569 dogs with MMVD and congestive heart failure of 10 days' duration or less. Dogs were randomized to furosemide plus a combination product containing benazepril and spironolactone, or furosemide plus benazepril alone. A significantly lower percentage of dogs treated with the combination reached the primary cardiac endpoint by day 360, with an odds ratio of 0.56 and a 95 percent confidence interval of 0.32 to 0.98 [3]. That is the strongest positive veterinary trial for spironolactone in MMVD.

A safety study followed 196 dogs with naturally occurring MMVD for a median of 217 days. Dogs received spironolactone at 2 mg/kg once daily or placebo, in addition to conventional therapy with an ACE inhibitor plus furosemide and digoxin if needed. Adverse events were similar between groups, and the percentage of dogs with out-of-range sodium, potassium, urea, or creatinine values was similar at each time point. Deaths from cardiac disease, renal disease, or both were more frequent in the reference group than in the spironolactone group [4]. That study supports the safety of spironolactone at the tested dose in this population.

A prospective trial in 67 Doberman pinschers with congestive heart failure from DCM tested spironolactone against placebo. Median time to the primary endpoint was 183 days in the spironolactone group and 124 days in the placebo group, a difference that did not reach statistical significance. Atrial fibrillation developed significantly less often in the spironolactone group, 7 dogs versus 15 dogs [5]. That arrhythmia signal is consistent with the antifibrotic mechanism described below.

A smaller placebo-controlled study in 18 dogs with advanced heart failure from degenerative valve disease or DCM found no survival difference when low-dose spironolactone was added to conventional therapy [6]. The dose used in that study was lower than the dose that produces full receptor blockade in the pharmacodynamic model, which is a plausible explanation for the negative result.

Clinical Trials in Cats

The SEISICAT pilot study enrolled 20 cats with heart failure from cardiomyopathy already receiving furosemide and an ACE inhibitor. Cats were randomized to spironolactone or placebo. At inclusion, several indices suggested the spironolactone group may have had less severe disease, which complicates interpretation. Of the spironolactone cats, 56 percent completed the 15-month period, compared with none of the placebo cats, and 2 of 9 spironolactone cats versus 9 of 11 control cats reached the primary endpoint [7]. The study is small and the baseline imbalance limits firm conclusions, but it supports the safety and possible benefit of spironolactone in cats with heart failure.

The Antifibrotic Rationale

The RALES trial in human medicine established that spironolactone reduces morbidity and mortality in advanced heart failure, and the benefit could not be explained by diuresis alone [1]. That finding redirected attention to the nonrenal actions of aldosterone receptor blockade. Aldosterone promotes myocardial and vascular fibrosis, endothelial dysfunction, and adverse remodeling. Blocking the receptor slows those processes [1][8].

Veterinary experimental work supports the same mechanism. In dogs with heart failure induced by rapid ventricular pacing, spironolactone prevented atrial electrical remodeling and reduced atrial fibrosis [9]. A separate study in the same model showed that spironolactone prevented ventricular electrogram widening, electrogram fractionation, interstitial fibrosis, and overexpression of inflammatory cytokines including interleukin-6 and tumor necrosis factor-alpha [10]. Spironolactone did not prevent left ventricular systolic dysfunction or chamber enlargement in that model, which fits the clinical picture: the drug does not reverse the primary myocardial disease, but it changes the substrate that generates arrhythmias and fibrosis.

The Doberman trial's reduction in atrial fibrillation is the clinical correlate of that experimental work [5]. The DELAY study tested spironolactone plus benazepril in dogs with preclinical MMVD and found a delay in the onset of heart failure and cardiac-related death, along with reduced progression of echocardiographic parameters and cardiac biomarkers [11]. A pilot study in compensated MMVD did not show a clear benefit, and the authors noted that a definitive trial would need a larger sample [12].

How Potassium-Sparing Diuretics Are Given

Spironolactone is given orally, usually once daily, and it can be given with or without food. The tablet is often compounded or split for small patients. Because the drug is a prodrug with active metabolites, the diuretic effect builds over several days. Owners should not expect a rapid change in urination after the first dose.

The standard veterinary approach is to add spironolactone to an existing heart failure regimen rather than to start it alone. In the BESST trial, the combination product containing benazepril and spironolactone was given with furosemide [3]. In the safety study, spironolactone was added to an ACE inhibitor with or without furosemide and digoxin [4]. In the Doberman trial, spironolactone was added to standard congestive heart failure therapy [5]. In the DELAY study, spironolactone was combined with benazepril in dogs not receiving other cardiac medications [11].

The dose should follow the product label or the prescribing veterinarian's instructions. The pharmacodynamic study identified 2 mg/kg as the dose that produced near-complete aldosterone blockade in the dog model [2], and the safety study used 2 mg/kg once daily [4]. The BESST trial used a fixed combination product at its label dose [3]. Doses should not be adjusted by owners, and dose changes should be paired with bloodwork.

If a dose is missed, the usual advice is to give it when remembered unless it is almost time for the next dose, in which case the missed dose is skipped. Doubling up is not appropriate because of the hyperkalemia risk.

Side Effects and What to Do About Them

The most important adverse effect of every drug in this class is hyperkalemia, an elevated serum potassium concentration. Potassium is critical for cardiac and neuromuscular function, and a high potassium can cause bradycardia, weak pulses, electrocardiographic changes, muscle weakness, and in severe cases cardiac arrest. Hyperkalemia is more likely when spironolactone is combined with an ACE inhibitor, an angiotensin receptor blocker, a potassium supplement, or another potassium-sparing diuretic.

Renal dysfunction is the second concern. Spironolactone can raise creatinine and blood urea nitrogen, particularly in patients with pre-existing kidney disease or volume depletion. In the MMVD safety study, out-of-range renal and electrolyte values occurred at similar rates in the spironolactone and placebo groups, which is reassuring at the tested dose in that population [4]. A retrospective study of 50 small dogs with MMVD receiving an ACE inhibitor plus spironolactone found no significant change in serum sodium or potassium over a mean follow-up of about 24 weeks. Serum magnesium increased significantly after 20 weeks [13]. That magnesium finding is worth knowing because magnesium retention can matter in patients with kidney disease.

Endocrine side effects are specific to spironolactone. Because it is not fully selective for the mineralocorticoid receptor, it can cause gynecomastia, mammary enlargement, and other antiandrogenic effects in some patients. Eplerenone was developed to reduce those effects [1].

Gastrointestinal signs, including vomiting and diarrhea, can occur. Lethargy and weakness can be signs of hyperkalemia or renal dysfunction and should prompt bloodwork rather than watchful waiting.

If an owner notices vomiting, diarrhea, weakness, collapse, a slow heart rate, or a sudden change in behavior, the patient should be evaluated promptly. If a pet on spironolactone is scheduled for surgery or anesthesia, the veterinary team should know about the drug because potassium and renal status affect anesthetic planning.

Which Animals Should Not Receive Potassium-Sparing Diuretics

Potassium-sparing diuretics are contraindicated in patients with hyperkalemia at baseline. They should be used with caution or avoided in patients with significant renal insufficiency, because reduced kidney function already limits potassium excretion. They should be avoided in patients with Addison's disease (hypoadrenocorticism), where aldosterone deficiency already causes potassium retention.

They should not be combined with potassium supplements or potassium-containing fluids unless the veterinarian has specifically planned for it and is monitoring closely. They should be used cautiously with ACE inhibitors and angiotensin receptor blockers because those drugs also reduce aldosterone signaling and raise potassium. The veterinary literature has historically advised caution when combining an ACE inhibitor with spironolactone, but the MMVD safety data showed no excess of adverse events at the tested dose [4], and the retrospective study in small dogs found no significant potassium change over time [13]. The practical position is that the combination is acceptable with monitoring, not that it is risk-free.

Patients with pre-existing electrolyte abnormalities, dehydration, or concurrent nephrotoxic drugs need individualized assessment. Pregnancy and breeding status should be discussed with the veterinarian because endocrine effects and fetal safety are not well characterized in veterinary species.

Drug Interactions

The most clinically important interactions are with other RAAS-blocking drugs. ACE inhibitors such as benazepril and enalapril reduce aldosterone production. Angiotensin receptor blockers such as telmisartan block the angiotensin II receptor. Both lower aldosterone signaling and raise potassium. Adding spironolactone on top of either increases the hyperkalemia risk further.

Potassium supplements and potassium-containing intravenous fluids add directly to the potassium load and should be avoided or used only with explicit monitoring.

Nonsteroidal anti-inflammatory drugs reduce renal blood flow and can worsen renal function and potassium retention. They are generally avoided in heart failure patients for that reason, independent of spironolactone.

Other diuretics interact in useful ways. Furosemide causes potassium loss, so combining it with spironolactone tends to balance potassium. Thiazide diuretics can cause hyponatremia and hypokalemia and may interact with potassium-sparing agents in complex ways.

Digoxin is commonly used in heart failure patients. Potassium status affects digoxin toxicity risk, because hypokalemia increases digoxin toxicity and hyperkalemia can be a sign of digoxin toxicity. That is another reason to monitor potassium in patients on multiple cardiac drugs.

How Potassium-Sparing Diuretics Compare With the Main Alternatives

Furosemide is the workhorse diuretic in veterinary cardiology. It acts on the thick ascending limb of the loop of Henle, produces rapid and powerful diuresis, and is the drug of choice for acute pulmonary edema. Its main drawbacks are potassium and magnesium wasting, activation of the RAAS, and the need for dose escalation over time. Spironolactone is not a substitute for furosemide. It is a complement.

ACE inhibitors and angiotensin receptor blockers reduce RAAS activity upstream of aldosterone. They lower aldosterone production rather than blocking its receptor. Combining them with spironolactone blocks the system at two points, which is why the combination is used in heart failure but also why potassium must be watched.

Pimobendan is an inodilator that improves systolic function and reduces afterload. It is not a diuretic and does not affect potassium directly, but it is part of the standard heart failure regimen into which spironolactone is added.

Thiazide diuretics act on the distal convoluted tubule and are used more in human medicine than in veterinary cardiology. They cause potassium loss and are not potassium-sparing.

Amiloride and triamterene are the alternative potassium-sparing class. They block the epithelial sodium channel directly. They are used rarely in veterinary cardiology, and their main advantage is that they do not cause the endocrine side effects of spironolactone. Their main disadvantage is that they lack the antifibrotic and neurohormonal benefits of aldosterone receptor blockade.

Eplerenone is the alternative aldosterone receptor antagonist. It is more selective and has fewer antiandrogenic effects. It has shown benefit in canine heart failure models [1], but clinical veterinary dosing and experience are limited compared with spironolactone.

Monitoring Potassium and Renal Function

Monitoring is the core of safe use. The minimum dataset is serum potassium, creatinine, and blood urea nitrogen, with sodium and magnesium as useful additions. A baseline panel should be obtained before starting spironolactone or changing its dose. A repeat panel should be obtained after starting or changing the dose, typically within one to two weeks, and then at intervals determined by the patient's stability and concurrent drugs.

The monitoring plan should account for the whole regimen, not just spironolactone. A dog on furosemide, an ACE inhibitor, pimobendan, and spironolactone has four drugs that can affect potassium or renal function. A cat on furosemide, an ACE inhibitor, and spironolactone has three. The more RAAS-blocking drugs on board, the more important the follow-up panel becomes.

Owners can help by reporting changes in water intake, urination, appetite, energy, and breathing. A sudden decrease in urination or a sudden increase in weakness can be a sign of hyperkalemia or renal dysfunction and warrants a call to the veterinarian.

If potassium rises above the reference range, the response depends on the magnitude and the clinical picture. Options include reducing the spironolactone dose, stopping it temporarily, adjusting the ACE inhibitor or angiotensin receptor blocker, stopping potassium supplementation, or treating the hyperkalemia directly. These decisions belong to the veterinarian.

Clinical Relevance, Limitations and Common Mistakes

Potassium-sparing diuretics matter in veterinary cardiology because they address a hormonal and structural problem that furosemide cannot. The RAAS is chronically activated in heart failure, and aldosterone is a major driver of sodium retention, potassium loss, fibrosis, and arrhythmia. Blocking the mineralocorticoid receptor changes that picture. The BESST trial showed a lower rate of the primary cardiac endpoint in dogs with MMVD and congestive heart failure treated with benazepril plus spironolactone compared with benazepril alone [3]. The Doberman trial showed less atrial fibrillation in the spironolactone group [5]. Experimental work showed reduced atrial and ventricular fibrosis [9][10]. The DELAY study showed delayed onset of heart failure in preclinical MMVD with spironolactone plus benazepril [11].

The limitations are equally clear. Not every trial has been positive. The small advanced heart failure study found no survival benefit at a low dose [6], which highlights the difference between a receptor-blocking dose and a token dose. The cat evidence is limited to a small pilot study with baseline imbalances [7]. The drug does not reverse the underlying valve or muscle disease. It does not replace furosemide for acute edema. It does not work quickly.

Common mistakes include:

Starting spironolactone without a baseline potassium and creatinine
Failing to recheck potassium and renal values after starting or changing the dose
Combining spironolactone with an ACE inhibitor, an angiotensin receptor blocker, and a potassium supplement without recognizing the additive hyperkalemia risk
Using a dose too low to block the receptor and then concluding the drug does not work
Expecting spironolactone to control acute pulmonary edema
Stopping furosemide because spironolactone was added
Ignoring vomiting, diarrhea, weakness, or a slow heart rate in a patient on a potassium-sparing diuretic
Forgetting to tell the veterinarian about all supplements, including potassium-containing products

Individual patients vary in their potassium and renal response, so the monitoring plan should be tailored by the treating veterinarian.

Frequently Asked Questions

What is a potassium-sparing diuretic?

A potassium-sparing diuretic is a drug that increases sodium and water excretion while conserving potassium. In veterinary medicine the class includes aldosterone receptor antagonists such as spironolactone and eplerenone, and epithelial sodium channel blockers such as amiloride and triamterene.

Why is spironolactone used in dogs with heart failure?

Spironolactone blocks aldosterone, reduces sodium retention, limits potassium loss, and has antifibrotic and antiarrhythmic effects. It is added to furosemide plus an ACE inhibitor or pimobendan in myxomatous mitral valve disease and dilated cardiomyopathy.

Does spironolactone replace furosemide?

No. Spironolactone is a weak diuretic and works slowly. Furosemide remains the drug that clears pulmonary edema. Spironolactone is added on top of furosemide, not instead of it.

What blood tests are needed on a potassium-sparing diuretic?

Serum potassium, creatinine, and blood urea nitrogen are the core tests, with sodium and magnesium as useful additions. A baseline panel is needed before starting, and a repeat panel is needed after starting or changing the dose.

Can spironolactone cause high potassium?

Yes. Hyperkalemia is the main adverse effect. The risk rises when spironolactone is combined with an ACE inhibitor, an angiotensin receptor blocker, a potassium supplement, or another potassium-sparing diuretic.

Is spironolactone safe to give with an ACE inhibitor?

The combination is commonly used in veterinary heart failure and has been studied in dogs with myxomatous mitral valve disease. It is acceptable with monitoring, because both drugs can raise potassium.

Do cats with heart failure benefit from spironolactone?

A small pilot study in cats with cardiomyopathy-related heart failure suggested possible benefit and acceptable safety, but the study was small and the groups were not perfectly balanced at baseline. The decision should be made by the treating veterinarian.

What should I do if my pet vomits or seems weak on spironolactone?

Contact the veterinarian promptly. Vomiting, diarrhea, weakness, collapse, or a slow heart rate can be signs of hyperkalemia or renal dysfunction and need bloodwork rather than home monitoring.